Navigation Links
Lethal needle blight epidemic may be related to climate change

Increased summer precipitation apparently helping to spread spores of pathogen

Biologists studying a lethal blight of lodgepole pines in northwestern British Columbia present strong evidence in the September issue of BioScience that climate change is to blame for the outbreak. The blight, caused by the fungus Dothistroma septosporum, causes trees to lose their needles and, in the case of the British Columbia outbreak, eventually die. D. septosporum has long been recognized as a pathogen of pines, but although it is considered a serious disease of exotic plantations in the Southern Hemisphere, it has until now been considered a minor threat to northern temperate forests. Lodgepole pines are an economically important species, being used in construction and for pulp.

Alex Woods and his colleagues at the British Columbia Forest Service and the University of Alberta investigated climate records in the area of the outbreak. The records provided no evidence of warming in the affected area in recent years, but they did reveal a clear increase in summer precipitation over the past decade. That constituted a smoking gun, because D. septosporum's life cycle depends on summer moisture for spore distribution. The increase in precipitation had no clear link to a known climatic oscillation that might have explained it, and the authors conclude that it is most likely related to a directional climate trend. The report of Woods et al. appears to represent one of a growing number of examples of an indirect effect of climate change, because increased summer precipitation would have been expected, absent D. septosporum, to benefit lodgepole pines.


'"/>

Source:American Institute of Biological Sciences


Page: 1

Related biology news :

1. New therapy for HIV/AIDS eliminates needles and excessive toxicity
2. High carbon dioxide levels spur Southern pines to grow more needles
3. Many needles, many haystacks
4. Researchers find gene that may be at root of potato blight
5. Potato blight pathogenicity explained by genome plasticity
6. Understanding biases in epidemic models important when making public health predictions
7. Researcher says flu responders can learn from 1918 epidemic
8. New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics
9. UGA study explains peaks and troughs of dengue epidemics
10. UGA researchers find that hunting can increase the severity of wildlife disease epidemics
11. US control strategies may make flu epidemics worse, UCLA study shows

Post Your Comments:
(Date:11/25/2009)...tate University assistant professors recently rece...(NSF) to continue research beneficial to understan...000. , Christopher Blackwood, assistant professo...arded grants to support two separate research proj...tter Decomposer Communities and Functions from the...
(Date:11/24/2009)...ence is opening new doors to understanding how sou...aring of a marine mammal or if they hear it at al...ay scanners that NASA uses to detect flaws in the ... allowing scientists to peek inside the giant head...e-dimensional replicas of a whale,s hearing anatom...
(Date:11/24/2009)...nd the American College of Medical Toxicology (ACM...publication of the Journal of Medical Toxicology ...g in March 2010. It was previously published by t...rnal of Medical Toxicology , an international, pee...science and practice of medical toxicology. The q...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Strep B Seems to Trick Immune System 51448 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 2National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 1National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 2
...ered that two microRNA (miRNA) molecules help cont...of B-cell chronic lymphocytic leukemia (B-CLL), th...r findings, published in the December 15 issue of ...ing as powerful regulators of gene expression in c... drug treatment, the investigators say. , In t...
...blem could be eliminated simply by dusting slag on...& Industry, the magazine of the SCI. , In the ...f damage annually. , Researcher David Cowen and...t applying slag to wheat growing in greenhouses ha...orporate the silica and express it as spiky struct...
... of plants to defend themselves by accumulating hi...me insects, and that such adaptation potentially e...ites may in turn evolve to deal with high levels o...zabeth Pilon-Smits of Colorado State University an...rnia, Berkeley, appear in the November 21st issue ...
Other Biology News:Pair of microRNA molecules controls major oncogene in most common leukemia 2New moth variety disarms plants guarded by selenium 2
(Date:11/24/2009)...24 NeurogesX, Inc. (Nasd...n developing and commercializing novel pain manage...no, President and Chief Executive Officer, is sche...Health Care Conference, to be held December 1-2, 2...York. ,, Mr. DiTonno and Stephen Ghiglieri, Ch...
(Date:11/24/2009)...ly approved the Promega PowerPlex 16 HS System for...g DNA records for the National DNA Index System. ...-- The FBI recently approved the Promega PowerPle...cipating in, or generating DNA records for, the Na...tains more than seven million profiles and has ass...
(Date:11/24/2009)...Newswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ... company, today,announced that it has submitted a ...rase alfa, the company,s enzyme replacement therap...er disease. This is the third marketing,applicatio...with previous,submissions in the United States and...
(Date:11/24/2009)...r 24 Health Robotics today announc... with a group of selected,investors. This recently...he,name Health Robotics Canada, Inc. and will mark...m of the Future concept, which includes the,revolu...T(TM), and OMM(TM).,Health Robotics Canada Inc. wi...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) to...e 3 clinical programs, Unit Dose Budesonide (UDB) ... treatment of migraine. For UDB, all,patients hav...itial Phase 3,clinical trial, and for MAP0004, the...in its initial Phase 3 clinical trial by the end o...
...of Schedule , , ST. LOUIS and RICHMOND, Calif., ... ) today announced it has reached a major producti...h Sigma-Aldrich Corporation (Nasdaq: SIAL ) to c...for research applications. The milestone triggers ...ng this production milestone more than one year ah...
...sset, Inc. (Nasdaq: VRUS ) announced today that ...reed with the FDA on the final design for a phase ...atitis C (HCV), slated to initiate in the first qu...8 is advancing into a large phase 2b trial," state...ical Officer. "R7128 is the most advanced nucleosi...
Other Biology Technology:MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 2Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5
Rabbit Anti-Mouse SHPRH Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Tyrosine Hydroxylase, phospho (Ser40) Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Biology Products: